evipedia.aidev
← Back to Review

Audit: QRS - Topical Naringenin for Hair Regrowth

Audit conducted on 26/06/2026 12:40 using AI4L / Opus 4.8

Iterations

Summary

Items Count
Total 91
Passed 86
Failed 0
N/A 5
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢  
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 “unvalidated in humans”, “by analogy with minoxidil”, “Speculative” preserved.
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 Pregnancy/breastfeeding kept as a contraindication.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢  
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 No PMIDs/NCTs/citations in QRS.
1.6 The QRS does not introduce new attributions. 🟢  

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢  
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢  
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢  
2.4 The QRS avoids language that implies medical or clinical advice 🟢  
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢  
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢  
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢  
2.8 Information is presented in a concise and very compact manner 🟢  
2.9 It DOES NOT address the reader directly 🟢  
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢  
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢  
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim. 🟢 No “anti-aging” usage.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt. 🟢  

3. Template Integrity

# Description Result Comments
3.1 The fixed labels and headings on the QRS are not modified (card/section headings, gate headings, tier labels, Monitoring column headers). 🟢 All fixed headings present and unmodified.
3.2 All “…” from the template are present in the QRS. 🟢 All template spans present; marker_#* and qualitative_item# instantiated.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢  

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. 🟢 Empty tiers hidden via display:none, not filled.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢  
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢  
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). 🟢 No emoji indicators present.
4.5 The QRS is designed to render on one A4 page. Over-budget sections are condensed, not extended onto a second page. 🟢  

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢  
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. 🟢  
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢  
5.4 All frontmatter values are trimmed: no leading/trailing whitespace, no surrounding quotes unless required by YAML. 🟢 duration quoted (contains colon).
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 line 4.
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 26.5.18.
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” 🟢 2026-0626-1145.
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: […]” 🟢 Opus.
5.9 The nickname of the AI is just a single word model name without version, etc. 🟢  
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: […]” 🟢 Opus 4.8.
5.11 The full name of the AI consists of the nickname and the model version number and no additional qualifier. 🟢  
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢  
5.13 All frontmatter values are trimmed: no leading/trailing whitespace, no surrounding quotes unless required by YAML. 🟢  

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] followed by “ - Quick Reference Sheet”, HTML-entity-encoded as needed. 🟢 “Topical Naringenin for Hair Regrowth - Quick Reference Sheet”.
6.2 [header_topic] is set to the [canonical_topic], with HTML entities encoded as needed. 🟢  
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 06/26/2026.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 Opus 4.8.
6.5 No additional header content appears: no badge, version stamp, AKA line, source-AI attribution, audit date, or QRS variant marker. 🟢  

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢  
7.2 [at_a_glance] is no longer than 60 words 🟢 52 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢  
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 “add-on” used instead of “adjunct”.
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢  
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢  

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
8.2 [stop_items] represent the Contraindications from the ER 🟢 All 4 “populations who should avoid” captured.
8.3 Individual [stop_items] are formatted as <li></li> 🟢  
8.4 Items are as concise as possible. No trailing explanations, elaborations, rationale, attributions, citations, study details, or content after a dash. 🟢  
8.5 Parenthetical qualifiers from the ER bullet ARE preserved as part of the item, kept concise. 🟢 “(cicatricial)” preserved.
8.6 When the ER uses ranking notation inside parens (e.g., “>”) that depends on an explanatory phrase, normalize to a plain comma-separated list. N/A ER contraindications use no ranking notation.
8.7 If no [stop_items] are present the section is left empty N/A stop_items are present.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
9.2 [caution_items] represent the Key Interactions from the ER, excluding any already listed as Contraindications 🟢  
9.3 Individual [caution_items] are formatted as <li></li> 🟢  
9.4 Items are as concise as possible. No trailing explanations, elaborations, rationale, attributions, citations, study details, or content after a dash. 🟢  
9.5 Parenthetical qualifiers from the ER bullet ARE preserved as part of the item, kept concise. 🟢 Example drug lists preserved.
9.6 When the ER uses ranking notation inside parens (e.g., “>”) that depends on an explanatory phrase, normalize to a plain comma-separated list. N/A ER interactions use no ranking notation.
9.7 If no [caution_items] are present the section is left empty N/A caution_items are present.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢  
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Concentration, Frequency, Combination.
10.3 If less than three distinct actionable aspects are mentioned, the unused sets are left empty and invisible, not filled with placeholders. 🟢 Three filled.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢  

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 ER provides one aspect; remaining two correctly hidden.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢  
11.3 If less than three distinct time-to-effect aspects are mentioned, the unused sets are left empty and invisible, not filled with placeholders. 🟢 time_2, time_3 hidden via display:none.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢  
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A ER provides time-to-effect information.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢  
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢  
12.3 Items are as concise as possible. No explanations, effect sizes, qualifiers, attributions, citations, study details, or mechanistic explanations. 🟢  
12.4 Parenthetical content is stripped, NOT preserved. 🟢  
12.5 If no items of a sub-section are present the respective span is set to display=none, not filled with empty-state phrasing. 🟢 high/medium hidden.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢  
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢  
13.3 Items are as concise as possible. No explanations, effect sizes, qualifiers, attributions, citations, study details, or mechanistic explanations. 🟢  
13.4 Parenthetical content is stripped, NOT preserved. 🟢  
13.5 If no items of a sub-section are present the respective span is set to display=none, not filled with empty-state phrasing. 🟢 high/medium hidden.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢  
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 Ferritin, TSH, Vitamin D, Serum zinc.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency from the ER. Not placeholder or empty. 🟢  

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢  
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All 4 qualitative markers captured.

Issues 26/06/2026 12:40

Pass rate 100.00%. No issues found.